Form 8-K - Current report:
SEC Accession No. 0001193125-25-183073
Filing Date
2025-08-19
Accepted
2025-08-19 08:06:45
Documents
13
Period of Report
2025-08-19
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d938122d8k.htm   iXBRL 8-K 23226
2 EX-99.1 d938122dex991.htm EX-99.1 8818
  Complete submission text file 0001193125-25-183073.txt   152818

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA rntx-20250819.xsd EX-101.SCH 2855
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE rntx-20250819_lab.xml EX-101.LAB 18756
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE rntx-20250819_pre.xml EX-101.PRE 11713
16 EXTRACTED XBRL INSTANCE DOCUMENT d938122d8k_htm.xml XML 3794
Mailing Address 12407 N. MOPAC EXPY. SUITE 250 #390 AUSTIN TX 78758
Business Address 12407 N. MOPAC EXPY. SUITE 250 #390 AUSTIN TX 78758 7378021989
Rein Therapeutics, Inc. (Filer) CIK: 0001420565 (see all company filings)

EIN.: 134196017 | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)